Nov 2021: Ensimmäinen kliininen tutkimus Etelä-Korean kotitekoisesta seuraavan sukupolven kimeerisestä antigeenireseptori T (CAR-T) -soluterapiasta, joka on suunniteltu kiertämään immuunitarkistuspisteiden signaaleja, on hiljattain käynnistynyt.
Korea Advanced Institute of Science and Technology (KAIST) ilmoitti keskiviikkona, että sen CAR-T-soluterapian vaiheen 1b kliininen tutkimus on parhaillaan käynnissä Samsung Medical Centerissä Soulissa. Koe suoritetaan 10 korealaisella potilaalla, joilla on uusiutunut ja refraktiivinen diffuusi suuri B-solulymfooma. Putken markkinointioikeudet siirtyivät yliopistolta Curocell-yritykselle, jonka perustaja oli professori Kim Chan-hyuk. Curocell vastaa vallankumouksellisen kliinisestä kehitysohjelmasta immunoterapia.
In addition, a Phase 2 Kliinisessä tutkimuksessa involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kimeerinen antigeenireseptori T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Haluat ehkä lukea: CAR T-soluterapia Koreassa
Tutkimuksen tulokset esiteltiin artikkelissa, joka julkaistiin verkossa Molecular Therapy -lehden lokakuun numerossa.
